Climb Bio Inc (CLYM) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Climb Bio Inc (CLYM) posted $0 in revenue for fiscal 2025, with a net loss of $59.85M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Climb Bio Inc
Climb Bio Inc has grown revenue from — to $0 over the last 6 fiscal years.
It clears 1 of 4 deterministic health checks. Nothing in the filed statements trips our red-flag scan.
Synthesised from Climb Bio Inc's SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Climb Bio Inc? Check it against the filing
Open the full tool →Paste a headline number you saw about CLYM — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Climb Bio Inc revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-20.67M | $-47.48M | $-45.24M | $-35.12M | $-73.90M | $-59.85M |
| Net margin | — | — | — | — | — | — |
Source: Climb Bio Inc SEC filings (10-K).
Climb Bio Inc financial health: 1 of 4 checks passed
- ✗Profitable every year (last 5)
- ✓More cash than total debt (cash 101.1M vs debt 0M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Free cash flow positive (latest yr) (-54.5M)
Checks computed deterministically from filed annual statements — no AI judgement.
Climb Bio Inc: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
Explore 6 years of Climb Bio Inc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track CLYM in your portfolio →
Climb Bio Inc financial history
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio Inc — frequently asked questions
What is Climb Bio Inc's revenue?
Climb Bio Inc (CLYM) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Climb Bio Inc profitable?
No — CLYM reported a net loss of $-59.85M in fiscal 2025.
What is Climb Bio Inc's market cap?
Climb Bio Inc (CLYM) has a market capitalization of about $614.43M, based on the latest data in our nightly-refreshed cache.
When does Climb Bio Inc's fiscal year end?
CLYM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Climb Bio Inc's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.